Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus GG + Lactobacillus rhamnosus
- Development stage
- Preclinical
- Lead developer
- Sherwood Gorbach
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Vaginal, Topical
01
Overview
Lactobacillus GG + Lactobacillus rhamnosus is a combination probiotic product. It contains the specific, extensively studied strain *Lactobacillus rhamnosus* GG (LGG), combined with at least one other unspecified strain from the *Lactobacillus rhamnosus* species. [12, 15, 17, 19] LGG, isolated in 1983 by scientists Sherwood Gorbach and Barry Goldin, is renowned for its ability to survive passage through the gastrointestinal tract, adhere to the intestinal lining, and confer various health benefits. [18, 21, 23] Probiotics are live microorganisms which, when administered in adequate amounts, provide a health benefit to the host. [2] The mechanisms of action for *L. rhamnosus* strains involve modulating the gut microbiome, strengthening the intestinal barrier, producing antimicrobial substances, and interacting with the host's immune system. [2, 3, 9, 22] This combination is typically used as a dietary supplement to support digestive and immune health. [4, 8, 24]
- Brand names
- CulturelleLACTOGG
- Other names
- Lactobacillus rhamnosus GG + Lactobacillus rhamnosus
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Lactobacillus GG + Lactobacillus rhamnosus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus GG + Lactobacillus rhamnosus.